Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Bone-targeted agents
5 evidence topics · 6 sources
FDA-approved indications
Denosumab versus zoledronic acid in castration-resistant disease with bone metastases
“Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8–24·9) with denosumab compared with 17·1 months (15·0–19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71–0·95; p=0·0002 for non-inferiority; p=0·008 for superiority).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p=0·09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronic acid versus placebo in metastatic prostate cancer
| Study | Patients with a skeletal-related event, zoledronic acid 4 mg | Patients with a skeletal-related event, placebo | Median days to first skeletal-related event, zoledronic acid 4 mg | Median days to first skeletal-related event, placebo | Hazard ratio for first skeletal-related event (95% CI) |
|---|---|---|---|---|---|
| Prostate cancer study | “33%” | “44%” | “Not Reached” | “321” | “0.67 (0.49, 0.91)” |